Want to see PLRX full AI Analyst Report?
Top Page
Pliant Therapeutics
(NASDAQ:PLRX)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.00
▼(-24.81% Downside)
Action:Reiterated
Date:07/14/26
The score is primarily held down by weak financial performance (no revenue, ongoing losses, and continued cash burn with a shrinking equity cushion). Technicals also lean bearish with the stock trading below key moving averages and negative MACD. A modest offset comes from the positive governance/R&D oversight board additions, while valuation support is limited due to a negative P/E and no dividend yield data.
Positive Factors
R&D governance strengthened
Adding two independent directors with scientific credentials and placing them on the R&D committee (one as chair) increases technical oversight and strategic guidance. This durable governance improvement can raise trial design quality, regulatory preparedness, and partner confidence, improving long-term execution of the pipeline.
Negative Factors
No commercial revenue
Absence of product revenue leaves the company fully dependent on development progress and external funding. This structural lack of recurring income increases execution risk, limits visibility into sustainability, and makes long-term operations contingent on successful clinical outcomes or partner deals.
Read all positive and negative factors
Positive Factors
Negative Factors
R&D governance strengthened
Adding two independent directors with scientific credentials and placing them on the R&D committee (one as chair) increases technical oversight and strategic guidance. This durable governance improvement can raise trial design quality, regulatory preparedness, and partner confidence, improving long-term execution of the pipeline.
Read all positive factors
Pliant Therapeutics (PLRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$66.25M
Dividend YieldN/A
Average Volume (3M)581.13K
Price to Earnings (P/E)―
Beta (1Y)1.18
Revenue GrowthN/A
EPS Growth49.00%
CountryUS
Employees49
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.84
Shares Outstanding61,920,250
10 Day Avg. Volume902,150
30 Day Avg. Volume581,135
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-0.58
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$2.67Price Target Upside100.50% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-1.41
Revenue Forecast (FY)N/A
Pliant Therapeutics Business Overview & Revenue Model
Company Description
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship i...
How the Company Makes Money
Pliant Therapeutics does not have a broadly established, recurring product-revenue business model from marketed drugs; as a clinical-stage biotechnology company, its revenue (if any in a given period) is primarily generated through collaboration a...
Pliant Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 1.58M | 9.69M | 7.57M |
| Gross Profit | -711.00K | -1.70M | 0.00 | 1.58M | 9.69M | 7.57M |
| EBITDA | -107.98M | -145.09M | -205.16M | -158.23M | -118.85M | -95.73M |
| Net Income | -113.22M | -149.34M | -210.30M | -161.34M | -123.32M | -97.26M |
Balance Sheet | ||||||
| Total Assets | 202.60M | 225.23M | 396.95M | 512.15M | 350.61M | 221.22M |
| Cash, Cash Equivalents and Short-Term Investments | 170.89M | 190.94M | 355.72M | 494.25M | 331.19M | 200.60M |
| Total Debt | 28.78M | 29.11M | 60.19M | 11.37M | 15.81M | 7.19M |
| Total Liabilities | 37.43M | 44.02M | 92.87M | 38.58M | 37.27M | 22.16M |
| Stockholders Equity | 165.17M | 181.21M | 304.08M | 473.58M | 313.34M | 199.06M |
Cash Flow | ||||||
| Free Cash Flow | -98.81M | -128.71M | -159.35M | -117.28M | -96.39M | -77.40M |
| Operating Cash Flow | -98.70M | -128.34M | -155.50M | -116.36M | -94.63M | -75.44M |
| Investing Cash Flow | 61.08M | 134.29M | 140.34M | -127.01M | -150.20M | 73.70M |
| Financing Cash Flow | -32.12M | -31.70M | 23.12M | 274.40M | 226.85M | 2.53M |
Pliant Therapeutics Technical Analysis
Negative
1.33
Price Trends
1.16
Negative
1.22
Negative
1.31
Negative
Market Momentum
-0.02
Positive
43.12
Neutral
29.68
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLRX, the sentiment is Negative. The current price of 1.33 is above the 20-day moving average (MA) of 1.13, above the 50-day MA of 1.16, and above the 200-day MA of 1.31, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 43.12 is Neutral, neither overbought nor oversold. The STOCH value of 29.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PLRX.
Pliant Therapeutics Risk Analysis
Pliant Therapeutics disclosed 83 risk factors in its most recent earnings report. Pliant Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pliant Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $167.80M | 1.55 | 55.29% | ― | -100.00% | ― | |
53 Neutral | $430.21M | ― | -22.51% | ― | 1199.64% | 30.81% | |
53 Neutral | $156.17M | ― | -61.43% | ― | -100.00% | 18.25% | |
52 Neutral | $268.07M | -2.62 | -94.90% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $18.41M | -0.15 | 1823.49% | ― | ― | 35.04% | |
44 Neutral | $66.25M | -0.58 | -59.06% | ― | ― | 49.00% |
* Healthcare Sector Average
PLRX
Pliant Therapeutics
1.10
-0.48
-30.38%
ORMP
Oramed Pharm
4.02
1.88
87.50%
OVID
Ovid Therapeutics
2.38
1.68
240.00%
IFRX
InflaRx
1.80
0.94
109.79%
EQ
Equillium
2.76
2.35
569.90%
QNCX
Quince Therapeutics
18.54
-353.46
-95.02%
Pliant Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Pliant Therapeutics adds independent directors to strengthen R&D
Positive
Jul 13, 2026
On July 9, 2026, Pliant Therapeutics, Inc. expanded its Board of Directors from seven to nine members and appointed Robert Iannone, M.D., M.S.C.E. as a Class I director and Flavia Borellini, Ph.D. as a Class II director, filling the newly created ...
Executive/Board ChangesShareholder Meetings
Pliant Therapeutics Shareholders Approve Directors and Executive Pay
Neutral
Jun 11, 2026
Pliant Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 11, 2026, with 61,914,664 common shares eligible to vote as of the April 15, 2026 record date. Shareholders elected Bernard Coulie, M.D., Ph.D., MBA, Gayle Crowell, and...
Business Operations and StrategyExecutive/Board Changes
Pliant Therapeutics Announces Board Retirements and Option Repricing
Neutral
Apr 17, 2026
Pliant Therapeutics announced that on April 14 and April 16, 2026, directors David E.I. Pyott and Katharine Knobil, M.D., notified the company of their plans to retire from its board and committees effective at the 2026 Annual Meeting of Stockhold...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.